Table 2. Review of the literature focusing on HRPT2-related HPT (period 2002-2013).
| Reference | Family (n) | Affected patients (n) | Patients with PHPT (n) | Single-gland involvement (n) | Synchronous multiglandular involvement (n) | Recurrences (n) | Jaw-Tumor (n) | Parathyro id Carcinom a (n) | Renal lesions (n) | Uterine lesions (n) | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Carpten (1) | 14 | 66 | 66/66 | NA | NA | NA | 30/66 | 11/66 | 18/66 | NA | |||
| Shattuck (19) | 3 | 3 | 3/3 | NA | NA | NA | NA | 3/3 | NA | NA | |||
| Howell (20) | 3 | 7 | 7/7 | NA | NA | 0/7 | 0/7 | 3/7 | 0/7 | NA | |||
| Simonds (21) | 1 | 4 | 4/4 | 4/4 | 0/4 | 0/4 | 0/4 | 1/4 | 0/4 | NA | |||
| Cetani (22) | 2 | 4 | 4/4 | 3/4 | 1/4 | NA | 0/4 | 0/4 | 0/4 | NA | |||
| Villablanca (23) | 2 | 9 | 9/9 | 7/9 | 2/9 | 3/9 | 0/9 | 0/9 | 0/9 | NA | |||
| Cavaco (24) | 6 | 11 | 9/11 | 5/9* | 1/9* | 0/9 | 2/11 | 0/11 | 2/11 | NA | |||
| Howell (25) | 1 | 2 | 2/2 | 2/2 | 0/2 | 0/2 | 1/2 | 0/2 | NA | NA | |||
| Gimm (26) | 1 | 3 | 3 | NA | NA | 1/3 | NA | 1/3 | NA | NA | |||
| Bradley (3) | 2 | 11 | 9 | NA | NA | NA | 0/11 | 2/11 | 0/11 | 6/7 | |||
| Moon (27) | 1 | 2 | 2 | 2/2 | 0/2 | NA | 1/2 | 2/2 | NA | NA | |||
| Mizusawa (28) | 3 | 7 | 7/7 | 6/7** | NA** | 1/7 | 1/7 | 1/7 | 0/7 | 0/3 | |||
| Aldred (29) | 1 | 3 | 3/3 | 3/3 | 0/3 | 0/3 | 2/3 | 0/3 | NA | NA | |||
| Bradley (30) | 5 | 5 | 5/5 | 4/5 | 1/5 | NA | 2/5 | 0/5 | 0/5 | 1/4 | |||
| Juhlin (31) | 1 | 1 | 1/1 | 1/1 | 0/1 | NA | NA | 0/1 | NA | NA | |||
| Guarnieri (32) | 1 | 5 | 4/5 | 4/4 | 0/4 | 1/4 | NA | 1/5 | 0/4 | 2/3 | |||
| Kelly (33) | 1 | 2 | 2/2 | 1/2 | 1/2 | 2/2 | NA | 2/2 | NA | NA | |||
| Yamashita (34) | 1 | 1 | 1/1 | 1/1 | 0/1 | 0/1 | 1/1 | 0/1 | NA | NA | |||
| Cetani (35) | 1 | 1 | 1/1 | 1/1 | 0/1 | 1/1 | 0/1 | 0/1 | 0/1 | NA | |||
| Cetani (36) | 2 | 3 | 3/3 | NA | NA | NA | NA | 3/3 | NA | NA | |||
| Raue (37) | 1 | 2 | 2/2 | 1/2 | 1/2 | NA | 1/2 | 1/2 | NA | NA | |||
| Cetani (38) | 1 | 1 | 1/1 | 1/1 | 0/1 | NA | 0/1 | 1/1 | NA | NA | |||
| Sarquis (8) | 3 | 11 | 11/11 | 5/11 | 6/11 | 8/11 | 1/11 | 1/11 | 4/11 | 5/6 | |||
| Guarnieri (39) | 4 | 9 | 6/9 | 6/6 | 0/6 | 3/6 | 0/9 | 3/9 | 3/9 | NA | |||
| Howell (40) | 1 | 1 | 1/1 | 1/1 | 0/1 | 0/1 | NA | NA | NA | NA | |||
| Silveira (18) | 1 | 9 | 9/9 | 3/9 | 6/9 | 6/9 | 0/9 | 1/9 | 4/9 | 5/9 | |||
| Iacobone (5) | 3 | 17 | 16/17 | 15/16*** | 0/16*** | 3/16 | 1/17 | 1/17 | 1/17 | 8/13 | |||
| Rekik (41) | 1 | 1 | 1/1 | 1/1 | 0/1 | 0/1 | 1/1 | 0/1 | 0/1 | 1/1 | |||
| Panicker (42) | 1 | 6 | 5/6 | NA | NA | 0/5 | 1/6 | 0/6 | 0/6 | 1/2 | |||
| Cavaco (43) | 2 | 2 | 2/2 | 2/2 | 0/2 | 1/2 | 0/2 | 2/2 | 0/2 | 0/2 | |||
| Pichardo-Lowden (16) | 1 | 1 | 1/1 | 1/1 | 0/1 | 1/1 | 0/1 | 0/1 | 1/1 | NA | |||
| Domingues (44) | 1 | 1 | 1/1 | 1/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | NA | |||
| Bricaire (45) | 15 | 13 | 12/13 | NA | NA | NA | 3/15 | 2/15 | 2/15 | 2/6 | |||
| Total | 87 | 224 | 213/224 | 78.7% | 21.3 | 29.5% | 23.5% | 18.7% | 17.4% | 50% | |||
| Present series | 7 | 16 | 16/16 | 11/16 (68.8%) | 5/16 (31.3%) | 4/16 (25.0%) | 2/16 (12.5%) | 6/16 (37.5%) | 3/16 (18.8%) | 2/6 (33.3%) | |||
*
Three patients with known PHPT were not operated on; pathology (gland no., histology) unknown.
**
Information concerning gland involvement not available for the patient with PHPT and parathyroid carcinoma.
***
One patient with known PHPT was not operated on; pathology (gland no., histology) unknown